Durham, N.C. – May 29, 2013 – Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the transmission of a live satellite feed of a clinical case using the new Tryton Side Branch SHORT Stent to an audience of several hundred interventional cardiologists at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.

The live procedure was performed May 22 from the Erasmus Medical Center in Rotterdam, the Netherlands by Nicolas Van Mieghem, M.D. "This case was a real-world example of the benefits a dedicated bifurcated stent can offer in daily practice when treating a challenging lesion," said Maceij Lesiak, M.D., co-chairman of the session on "Complex Bifurcation Stenting".

"The live case reinforced that the Tryton Side Branch Stent enables physicians to treat complex bifurcated coronary disease in a straightforward manner," said Shawn P. McCarthy, president and CEO of Tryton Medical. "Panelists commented that Dr. Van Mieghem maintained total control treating the complex bifurcation and achieved a successful outcome."

McCarthy continued, "This was a tremendous EuroPCR for Tryton Medical. The new Tryton Side Branch SHORT Stent was well-received by physicians, award-winning data was presented supporting Tryton’s dedicated bifurcation stenting as a treatment strategy, we held a world-class symposium featuring new data on use of the Tryton Stent for left main disease, and we capped the week announcing our participation in the prestigious Nordic-Baltic Dedicated Bifurcation Trial."

Presentations confirmed consistent clinical results with the Tryton Side Branch Stent:

- A clinical symposium featured a comprehensive overview of Tryton Side Branch Stent clinical evidence, chaired by leading physicians Martin B. Leon M.D. and Patrick W. Serruys M.D. At the symposium, Antonio Bartorelli, M.D. of Centro Cardiologico Monzino in Italy, highlighted the Tryton IDE study as a landmark study in the treatment of coronary bifurcation disease and anticipated the outcomes of this study to be presented at TCT later this year.
• Jens F. Lassen, M.D. of Aarhus University Hospital in Skejby, Denmark announced, on behalf of the Nordic-Baltic Bifurcation Study Group, the Nordic-Baltic Dedicated Bifurcation Trial comparing use of final kissing balloon compared to no final kissing balloon in a prospective, controlled, randomized, multicenter clinical trial. In addition, he noted that the Tryton Side Branch Stent is the latest evolutionary step in the treatment of bifurcation disease.

• Robert-Jans van Geuns, M.D. of Erasmus Medical Center in Rotterdam, the Netherlands presented the one month clinical follow-up data of 30 patients in the prospective clinical ‘first in human’ registry treating patients with left main disease. "Excellent acute gain and angiographic results in three segments of the bifurcation is obtained," concluded Dr. van Geuns. He added, "the newly CE-marked Tryton Side Branch SHORT Stent will broaden the treatment options in patients with a short main branch landing zone."

• A clinical case using a Tryton Side Branch Stent was awarded the "Best Clinical Case of EuroPCR 2013". The award was presented on May 24 in main arena for work by Joanna Wykrzykowska, M.D. on the topic of "Successful treatment of a complex bifurcation lesion with extensive side branch involvement with bioresorbable vascular scaffolds in combination with a dedicated bifurcation side branch stent: evaluation and new insights with 3D-OCT".

The Tryton Side Branch Stent is supported by robust clinical evidence in more than 1,000 patients. Published data in a patient pooled analysis from more than 900 patients treated with the Tryton Side Branch Stent in more than 8 European post-marketing registries demonstrated low target lesion revascularization rates of 2.9 percent at six months and 4.0 percent at one year, and a low 0.5 percent thrombosis rate at one year. More than 7,500 patients have been treated with the Tryton Side Branch Stent and it is commercially available throughout Europe, Russia and the Middle East. The new Tryton Side Branch SHORT Stent enables physicians to broaden treatment options in bifurcations in large vessels with a short main branch landing zone.

Tryton has completed enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent. The company anticipates study outcomes will be presented at TCT 2013 in San Francisco.

About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary
tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions. The Tryton Side Branch Stent has not been studied extensively in left main disease.

**About the Tryton Side Branch Stent System**
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

**About Tryton Medical, Inc.**
Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole of Spray Venture Partners to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3x5 Special Opportunity Fund. For more information please visit [www.trytonmedical.com](http://www.trytonmedical.com) and follow the company on Twitter at @TrytonMedical1.

# # #